Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis
暂无分享,去创建一个
Kutty Selva Nandakumar | M. Lagerquist | C. Ohlsson | R. Holmdahl | C. Jochems | H. Carlsten | C. Engdahl | U. Islander | M. Erlandsson
[1] M. Cutolo. Selective estrogen receptor agonism lacks clinical benefit in rheumatoid arthritis: comment on the article by van Vollenhoven et al. , 2010, Arthritis and rheumatism.
[2] G. Herrero-Beaumont,et al. Efficacy and safety of a selective estrogen receptor β agonist, ERB‐041, in patients with rheumatoid arthritis: A 12‐week, randomized, placebo‐controlled, phase II study , 2010, Arthritis care & research.
[3] A. Boots,et al. Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor α but not estrogen receptor β , 2010, Arthritis research & therapy.
[4] B. Dijkmans,et al. The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. , 2010, Arthritis and rheumatism.
[5] M. Lagerquist,et al. Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. , 2010, Arthritis and rheumatism.
[6] M. Lagerquist,et al. Long‐term anti‐arthritic and anti‐osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis , 2008, Clinical and experimental immunology.
[7] Kutty Selva Nandakumar,et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. , 2008, Arthritis & Rheumatism.
[8] M. Lagerquist,et al. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. , 2007, Arthritis and rheumatism.
[9] M. Terauchi,et al. IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation , 2007 .
[10] M. Terauchi,et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. , 2007, The Journal of clinical investigation.
[11] M. Stefanick. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. , 2005, The American journal of medicine.
[12] Kutty Selva Nandakumar,et al. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. , 2005, Journal of immunological methods.
[13] Don McNaughton,et al. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro , 2005, Arthritis research & therapy.
[14] Kutty Selva Nandakumar,et al. Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells. , 2005, Arthritis and rheumatism.
[15] C. Ohlsson,et al. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation , 2005, Arthritis research & therapy.
[16] M. Rowley,et al. An arthritogenic monoclonal antibody to type II collagen, CII‐C1, impairs cartilage formation by cultured chondrocytes , 2004, Immunology and cell biology.
[17] J. Lemmen,et al. Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. , 2004, Journal of molecular endocrinology.
[18] H. Offner,et al. Estradiol Treatment Redirects the Isotype of the Autoantibody Response and Prevents the Development of Autoimmune Arthritis 1 , 2003, The Journal of Immunology.
[19] Kutty Selva Nandakumar,et al. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. , 2003, The American journal of pathology.
[20] B. Komm,et al. Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease , 2003 .
[21] D. Mellström,et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. , 2003, The Journal of rheumatology.
[22] R. Holmdahl,et al. Genistein as an anti-inflammatory agent , 2003, Inflammation Research.
[23] D. Mellström,et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis , 2003, Annals of the rheumatic diseases.
[24] B. Komm,et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. , 2003, Endocrinology.
[25] C. Ohlsson,et al. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. , 2002, The Journal of endocrinology.
[26] Kutty Selva Nandakumar,et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. , 2002, Arthritis and rheumatism.
[27] S. Gabriel,et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. , 2002, Arthritis and rheumatism.
[28] H. Hagino,et al. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. , 2001, Bone.
[29] H. Carlsten,et al. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. , 2000, Cellular immunology.
[30] S. Adami,et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. , 2000, The Journal of rheumatology.
[31] L. Suva,et al. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro. , 2000, European journal of cancer.
[32] Chisato Miyaura,et al. Comparative Effects of Estrogen and Raloxifene on B Lymphopoiesis and Bone Loss Induced by Sex Steroid Deficiency in Mice , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] L. Joosten,et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis , 1999, Arthritis research.
[34] J. Gustafsson,et al. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. , 1999, The Journal of clinical investigation.
[35] C. Gardner,et al. Increases in osteocalcin after ovariectomy are amplified by LPS injection: strain differences in bone remodelling. , 1998, General pharmacology.
[36] J. Gustafsson,et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.
[37] A. Glasebrook,et al. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. , 1997, Science.
[38] A. Glasebrook,et al. Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.
[39] B. Månsson,et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. , 1995, The Journal of clinical investigation.
[40] D. Heinegård,et al. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.
[41] A. Tarkowski,et al. Histopathological and serological progression of experimental Staphylococcus aureus arthritis , 1992, Infection and immunity.
[42] A. Weisz,et al. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. , 1990, Nucleic acids research.
[43] R. Holmdahl,et al. Estrogen induced suppression of collagen arthritis. V: Physiological level of estrogen in DBA/1 mice is therapeutic on established arthritis, suppresses anti-type II collagen T-cell dependent immunity and stimulates polyclonal B-cell activity. , 1990, Journal of autoimmunity.
[44] R. Holmdahl,et al. Oestrogen induced suppression of collagen arthritis. IV: Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. , 1989, Journal of reproductive immunology.
[45] L. Aarden,et al. Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.
[46] R. Holmdahl,et al. Oestrogen‐Induced Suppression of Collagen Arthritis , 1987 .
[47] R. Holmdahl,et al. Female sex hormones suppress development of collagen-induced arthritis in mice. , 1986, Arthritis and rheumatism.
[48] L. Klareskog,et al. Homologous type II collagen induces chronic and progressive arthritis in mice. , 1986, Arthritis and rheumatism.